Official Title
Expanded Access Information for Physicians for Bamlanivimab (LY3819253) Emergency Investigational New Drug [EIND]
Brief Summary

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

No longer available
Individual Patients
COVID-19

Drug: Bamlanivimab

Administered intravenously (IV).
Other Name: Array

Eligibility Criteria

Inclusion Criteria:

- Reside in a country where there are ongoing Lilly-sponsored clinical trials (currently
this is only the United States)

- Present within 10 days of symptom onset

- Have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by reverse
transcription polymerase chain reaction (RT-PCR) within the last three days

- Participants greater than or equal to (≥) 65 years of age OR

- Participants ≥ 12 years of age who weigh at least 40 kilograms AND have at least one
of the following:

- Cancer

- Chronic kidney disease

- Chronic obstructive pulmonary disease (COPD) or other chronic lung disease

- Immunocompromised state (weakened immune system or on immunomodulatory
medications)

- Obesity (body mass index [BMI] of 35 or higher)

- Serious heart conditions such as heart failure, coronary artery disease or
cardiomyopathies

- Sickle cell disease

- Diabetes mellitus (Types 1 or 2)

Exclusion Criteria:

- Require hospitalization greater than (>) 24 hours or hospice care. Residents in long
term care or skilled nursing facilities that meet the inclusion criteria and are not
on mechanical ventilation will be considered

- Bamlanivimab should not be used in patients hospitalized with severe COVID-19
respiratory disease

Eligibility Gender
All
Eligibility Age
Minimum: 12 Years ~ Maximum: N/A

Contact Lilly at 1-800-LillyRx (1-800-545-5979), Study Director
Eli Lilly and Company

AbCellera Biologics Inc.
NCT Number
MeSH Terms
COVID-19
Bamlanivimab